Fulcrum Therapeutics (FULC) Stock Price, News & Analysis

Company Overview

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression. The company’s pipeline combines discovery-stage projects with clinical-stage assets, reflecting its commitment to translating foundational science into potential therapies for underserved genetic disorders.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Fulcrum maintains research and development facilities in both Cambridge and the San Francisco Bay Area. The company is led by President and Chief Executive Officer Steven L. Holtzman, whose leadership team includes professionals with extensive experience in drug development, regulatory affairs and commercial strategy. Fulcrum collaborates with patient advocacy groups, academic institutions and contract research organizations to advance its programs and broaden access to promising new treatments.

Fulcrum Therapeutics serves a global patient population by pursuing therapies for rare and serious genetic diseases with significant unmet medical need. The company’s integrated approach—combining a deep understanding of epigenetic mechanisms with state-of-the-art drug discovery capabilities—positions it to address complex disorders for which conventional therapeutic strategies have been largely ineffective.

Key Stats

• Today's Range: $8.66 to $9.18
• 50-Day Range: $6.34 to $9.63
• 52-Week Range: $2.32 to $9.88
• Volume: 244,889 shs
• Average Volume: 564,076 shs
• Market Capitalization: $472.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.60
• Consensus Rating: Moderate Buy

Fulcrum Therapeutics Stock Analysis - MarketRank™

Fulcrum Therapeutics scored higher than 24% of companies evaluated by MarketBeat, and ranked 861st out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Fulcrum Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside/Downside

The consensus price target for Fulcrum Therapeutics is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Fulcrum Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Fulcrum Therapeutics are expected to decrease in the coming year, from ($0.16) to ($1.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Fulcrum Therapeutics is -7.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Fulcrum Therapeutics is -7.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Fulcrum Therapeutics has a P/B Ratio of 1.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.82% of the outstanding shares of Fulcrum Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Fulcrum Therapeutics has a short interest ratio ("days to cover") of 5.6.

Change versus previous month

Short interest in Fulcrum Therapeutics has recently decreased by 0.81%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Fulcrum Therapeutics does not currently pay a dividend.

Dividend Growth

Fulcrum Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.82% of the outstanding shares of Fulcrum Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Fulcrum Therapeutics has a short interest ratio ("days to cover") of 5.6.

Change versus previous month

Short interest in Fulcrum Therapeutics has recently decreased by 0.81%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.55

News Sentiment

Fulcrum Therapeutics has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Fulcrum Therapeutics this week, compared to 3 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Fulcrum Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.00% of the stock of Fulcrum Therapeutics is held by insiders.

Percentage Held by Institutions

89.83% of the stock of Fulcrum Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

FULC Stock Analysis - Frequently Asked Questions

How have FULC shares performed this year?

Fulcrum Therapeutics' stock was trading at $4.70 at the start of the year. Since then, FULC stock has increased by 86.0% and is now trading at $8.74.

How were Fulcrum Therapeutics' earnings last quarter?

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) released its quarterly earnings data on Tuesday, July, 29th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.01.

When did Fulcrum Therapeutics IPO?

Fulcrum Therapeutics (FULC) raised $76 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 4,500,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and SVB Leerink acted as the underwriters for the IPO.

How do I buy shares of Fulcrum Therapeutics?

Shares of FULC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Fulcrum Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Fulcrum Therapeutics investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AUO (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 7/29/2025
• Today: 10/13/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:FULC
• CIK: 1680581
• Web: www.fulcrumtx.com
• Phone: (617) 651-8851
• Fax: N/A
• Employees: 100
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Fulcrum Therapeutics: $9.60
• High Price Target: $12.00
• Low Price Target: $5.00
• Potential Upside/Downside: +9.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$9.73 million
• Net Margins: N/A
• Pretax Margin: -0.64%
• Return on Equity: -31.05%
• Return on Assets: -28.96%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 24.42
• Quick Ratio: 24.42

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.51 per share
• Price / Book: 1.94

Miscellaneous

• Outstanding Shares: 54,092,000
• Free Float: 50,306,000
• Market Cap: $472.76 million
• Optionable: Optionable
• Beta: 2.93